Advance with

When you’re focusing on the future of cancer care, it helps to start with a clear and accurate picture of the present.


COTA leverages our proprietary abstraction technology and oncology expertise to curate meaningful, longitudinal, and de-identified data to enable insight generation.

We form flexible and collaborative partnerships with life science companies to shape the future of real-world evidence.


#6846 - COTA Healthcare homepage redesign - inform


Market of current oncologics and decisions to drive future therapeutic areas.

#6846 - COTA Healthcare homepage redesign - accelerate


Drug development and build real-world comparator arms.

#6846 - COTA Healthcare homepage redesign - inspire


New ways of thinking about how trials are designed.


Data Source



Curation Depth


COTA Featured in BioCentury – Real World Data’s Power to Increase Racial Diversity in Clinical Research

COTA’s Chief Medical Officer, Dr. C.K. Wang spoke with BioCentury to help further the conversation around the role of RWD in increasing racial diversity in clinical research.

Historical Regulatory Use of RWE

Historical uses of RWE in regulatory decision-making are at best sparse, but they provide the precedent on which we are building the foundation of real-world impact. This blog reviews use cases of RWE in regulatory actions.


COTA captures clinical data from EHR from multiple provider sources across the United States, including both academic and community cancer programs. We also use non-EHR sources such as publicly available and proprietary databases, to generate a rich and precise dataset for use by life sciences companies.

COTA collects all clinically-relevant data points to create a rich, in-depth longitudinal cancer patient journey from our healthcare providers’ EHR. Data elements captured may vary per cancer type, but generally, our data contains (but is not limited to) detailed demographic, pathologic, genomic, treatment, and outcomes data.

Life sciences companies have used our data to support HEOR, commercial assessments, and clinical development, including supplementing clinical trial data with RWD in the form of external comparator controls. We are open to discussing any other opportunities, as well as your data needs and how COTA can generate value for your organization.

We work with life science companies interested in using oncology RWD to accelerate drug development and bring clarity to cancer. We work with the top global pharmaceutical companies, though our partners range from multinational pharma to emerging biotechs.

Our collaborative and flexible approach enables us to succeed with emerging biopharma partners. We work alongside EBPs to provide analytical, medical, and strategic support to validate use of COTA data towards EBP goals.

Interested in learning more about how we can transform cancer care together?